About Junshi Biosciences
Junshi Biosciences is a publicly listed company based in Shanghai (China) founded in 2012. Antibody-based therapeutics are developed for cancer and other diseases. It operates on a HealthTech model. The company has 2,580 employees. Junshi Biosciences offers products and services including Toripalimab (Tuoyi® / LOQTORZI™), Adalimumab, and Oncoriximab. Its focus areas include Biotechnology and Biopharmaceuticals. Its legal entity is Shanghai Junshi Biosciences Co., Ltd.
Company details
Shanghai Junshi Biosciences Co., Ltd. is recognized as a prominent innovator in the biopharmaceutical sector in China. Established in 2012, the company is engaged in the research, development, production, and commercialization of novel biological drugs. Its therapeutic areas include oncology, autoimmune diseases, chronic metabolic disorders, neurological conditions, and infectious diseases. Key products such as Toripalimab, an anti-PD-1 monoclonal antibody, have gained approvals in China and the USA, marking significant milestones. With a global RD system and full lifecycle antibody development platforms, operations are supported across multiple locations in China and the USA.
- Headquarters Shanghai, China
- Employees 2,580
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website junshipharma.com
- Social LinkedIn
- Legal Name Shanghai Junshi Biosciences Co., Ltd. Class A
- Annual Revenue$355.66 M (USD)28.19as on Dec 31, 2025
- Net Profit-$125.01 M (USD)31.68as on Dec 31, 2025
- EBITDA-$87.89 M (USD)39.02as on Dec 31, 2025
- Latest Funding Round$31.48M (USD), Post-IPO
Feb 2018
- Employee Count2,580
Products & Services of Junshi Biosciences
Junshi Biosciences offers a comprehensive portfolio of products and services, including Toripalimab (Tuoyi® / LOQTORZI™), Adalimumab, and Oncoriximab.
Used for treating various advanced cancer types effectively.
Administered for managing autoimmune conditions like rheumatoid arthritis.
Designed to address chronic metabolic disorders in patients.
Funding Insights of Junshi Biosciences
- Total Rounds 1
- Last Round Post-IPO — $31.48M
- First Round $31.48M
(Feb 2018)
All 1 funding rounds of Junshi Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $31.48M | Post-IPO | – | – | – |
IPO & Listings of Junshi Biosciences
Junshi Biosciences is a publicly listed company on the SSE with ticker symbol 688180 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Dec 2018
- Listed onHKG: 1877
- Listed entityShanghai Junshi Biosciences Co., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE1000041Z1
- Share price30.44 CNY (-2.4% on the day) · 2026-10-14
- Market capitalisation27,571,003,798.33 CNY
- EPS (diluted, trailing year)-0.43 CNY
- Volume (last session)8,934,702
Financials of Junshi Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.49B CNY | -875.2M CNY | -615.3M CNY |
| 2024 | 1.94B CNY | -1.28B CNY | -1.01B CNY |
| 2023 | 1.50B CNY | -2.28B CNY | -2.18B CNY |
| 2022 | 1.45B CNY | -2.39B CNY | -2.45B CNY |
| 2021 | 4.03B CNY | -720.9M CNY | -414.1M CNY |
Detailed financial statements for Junshi Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Junshi Biosciences
3 dated milestones of Junshi Biosciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Junshi Biosciences is founded.
- Funding First funding round of $31.5M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Junshi Biosciences
The website of Junshi Biosciences (junshipharma.com) receives about 2.9K visits a month and ranks #3,800,614 among all websites worldwide, #4,862 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▼ 37.8% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,800,614
among all websites
- Category rank#4,862
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.1
- Average visit29 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Junshi Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cnpharm.com | cnpharm.com | 100% | – | ||
phirda.com | phirda.com | 86% | #762,386 | – | |
| cmocro.com | 86% | 21.8K | #1,242,657 | View details | |
drvoice.cn | drvoice.cn | 63% | #1,546,862 | – | |
jlszlyy.com | jlszlyy.com | 52% | #5,665,693 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Junshi Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Junshi Biosciences
Complete news archive for Junshi Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Junshi Biosciences
Junshi Biosciences was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Junshi Biosciences is headquartered in Shanghai, China.
Junshi Biosciences has 2,580 employees.
Annual revenue of Junshi Biosciences is $355.66M as on Dec 31, 2025.
Shanghai Junshi Biosciences Co., Ltd. is recognized as a prominent innovator in the biopharmaceutical sector in China. Established in 2012, the company is engaged in the research, development, production, and commercialization of novel biological drugs. Its therapeutic areas include oncology, autoimmune diseases, chronic metabolic disorders, neurological conditions, and infectious diseases. Key products such as Toripalimab, an anti-PD-1 monoclonal antibody, have gained approvals in China and the USA, marking significant milestones. With a global RD system and full lifecycle antibody development platforms, operations are supported across multiple locations in China and the USA.
Junshi Biosciences offers Toripalimab (Tuoyi® / LOQTORZI™), Adalimumab, and Oncoriximab.
Yes, Junshi Biosciences is publicly traded on SSE under the ticker symbol 688180.
Junshi Biosciences operates through Shanghai Junshi Biosciences Co., Ltd..